Dr Eric Chatelain

Dr Chatelain joined DNDi in July 2007 as a senior project manager focusing on screening and discovery projects for new drugs for the treatment of human African trypanosomiasis (HAT), leishmaniasis and Chagas disease.

Prior to joining DNDi, Dr Chatelain held various positions at Spirig Pharma Ltd., a Swiss-based company developing dermatology drugs. Most recently, he served as the Spirig Pharma’s Head of Preclinical Research.

Dr Chatelain completed postdoctoral fellowships at the Imperial Cancer Research Fund, in London, UK and the Friedrich Miescher Institute in Basel, Switzerland.

He earned his PhD in Biochemistry at the National Institute of Applied Sciences, Lyon France.